Topical cyclosporine hydrogel preparation: A new therapeutic option in the treatment of nail psoriasis.
cyclosporine
hydrogel ointment
nail psoriasis
topical therapy
treatment
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
19
09
2022
received:
23
08
2022
accepted:
05
10
2022
pubmed:
11
10
2022
medline:
21
12
2022
entrez:
10
10
2022
Statut:
ppublish
Résumé
Nail psoriasis is a chronic nail disorder that commonly affects psoriatic patients causing severe distress despite the limited body surface area. Treatments for nail psoriasis are limited, as nails are often difficult to treat with topical therapies, and among different systemic agents responses are unpredictable. We carried out a prospective study in order to analyze the effectiveness and tolerability of topical cyclosporine hydrogel ointment in nail psoriasis. Three patients, for a total of 44 nails, were treated with topical cyclosporine hydrogel ointment. All nails were evaluated, before starting the treatment, every 28 days and after 12 weeks of therapy, by the same dermatologists, through clinical and onychoscopic evaluations. The patients were also asked to assess on the compliance with product use. Complete response (CR) was observed in 2 of 3 patients; a partial response (PR) was observed in the other patient. Overall, 24 of 44 nails had CR and 20 had a PR. Cyclosporine hydrogel ointment has shown efficacy and safety in the treatment of nail psoriasis. The product has also been shown to be stable in composition, easy to apply and not discomfortable for the patient.
Substances chimiques
Cyclosporine
83HN0GTJ6D
Dermatologic Agents
0
Ointments
0
Hydrogels
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15917Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Rigopoulos D, Rompoti N, Gregoriou S. Management of nail psoriasis. Dermatol Clin. 2021;39(2):211-220. doi:10.1016/j.det.2020.12.014
Belyayeva E, Gregoriou S, Chalikias J, et al. The impact of nail disorders on quality of life. Eur J Dermatol. 2013;23(3):366-371. doi:10.1684/ejd.2013.2048
Balestri R, Rech G, Rossi E, et al. Natural history of isolated nail psoriasis and its role as a risk factor for the development of psoriatic arthritis: a single-centre cross-sectional study. Br J Dermatol. 2017;176(5):1394-1397. doi:10.1111/bjd.15026
Rigopoulos D, Baran R, Chiheb S, et al. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus. J Am Acad Dermatol. 2019;81(1):228-240. doi:10.1016/j.jaad.2019.01.072
Cannavò SP, Guarneri F, Vaccaro M, Borgia F, Guarneri B. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. Dermatology. 2003;206(2):153-156. doi:10.1159/000068469
Tosti A, Guerra L, Bardazzi F, Lanzarini M. Topical ciclosporin in nail psoriasis. Dermatology. 1990;180(2):110. doi:10.1159/000248005
Hermann RC, Taylor RS, Ellis CN, et al. Topical ciclosporin for psoriasis: in vitro skin penetration and clinical study. Skin Pharmacol Physiol. 1988;1(4):246-249. doi:10.1159/000210782
Prins AMA, Vos K, Franssen EJF. Instability of topical ciclosporin emulsion for nail psoriasis. Dermatology. 2007;215(4):362-363. doi:10.1159/000107635
Tamura T, Takayama K, Satoh H, Tanno K, Nagai T. Evaluation of oil/water-type cyclosporine gel ointment with commercially available oral solution. Drug Dev Ind Pharm. 1997;23(3):285-291. doi:10.3109/03639049709149805
Badihi A, Frušić-Zlotkin M, Soroka Y, et al. Topical nano-encapsulated cyclosporine formulation for atopic dermatitis treatment. Nanomedicine. 2020;24:102140. doi:10.1016/j.nano.2019.102140